Skip to Main Content.
Site navigation
Fidelity.com Home
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log Out
  • Accounts & Trade
    • Portfolio Log In Required
    • Portfolio
    • AccountPositions Log In Required
    • AccountPositions
    • Trade Log In Required
    • Trade
    • Trading Dashboard Log In Required
    • Trading Dashboard Log In Required
    • Active Trader Pro
    • Transfers
    • Cash Management Log In Required
    • Cash Management
    • Bill Pay Log In Required
    • Bill Pay
    • Full View Log In Required
    • Full View
    • Security Settings Log In Required
    • Security Settings
    • Account Features Log In Required
    • Account Features
    • Statements Log In Required
    • Statements
    • Fidelity Alternative Investments Program Log In Required
    • Tax Forms & Information
    • Retirement Distributions Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • New Account Checklist Log In Required
    • Lending Solutions-Line of Credit Log In Required
    • Refer a Friend
  • Planning & Advice
    • What We Offer
    • Build Your Plan
    • My Goals
    • Financial Basics
    • Building Savings
    • Robo Investing Plus Financial Advice
    • Wealth Management
    • Find an advisor
    • Retirement
    • Life Events
    • Saving & Investing for a Child
    • Charitable Giving
  • News & Research
    • News
    • Wealth Management Insights
    • Watch List Log In Required
    • Quotes
    • Quotes
    • Alerts Log In Required
    • Mutual Funds
    • Stocks
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Markets & Sectors
    • IPOs
    • Annuities
    • Learning Center
    • Notebook
    • Notebook
  • Investment Products
    • Mutual Funds
    • Retirement & IRAs
    • Stocks and Trading
    • Crypto
    • Direct Indexing
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Sustainable Investing
    • Cash Management & Credit Cards
    • Managed Accounts
    • 529 College Savings
    • Health Savings Accounts
    • Annuities
    • Life Insurance & Long Term Care
  • Why Fidelity
    • The Fidelity Advantage
    • Planning & Advice
    • Trading
    • Straightforward Pricing
    • Insights & Tools
    • Security & Protection
    • Marketplace Solutions
    • About Fidelity
    • Careers
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log Out
Content and data provided by various third parties and Fidelity − Terms of Use
  • Research >
  • Stocks >
  • News & Events >

Stock Details


  • Snapshot
  • Detailed Quote
  • Advanced Chart &
    Technical Analysis Opens in New Window
  • News & Events
  • Compare
  • Analyst Opinions
  • Research Reports
  • Key Statistics
  • Earnings
  • Dividends
  • Ownership & Insiders
  • Financial Statements
  • SEC Filings

RELATED RESOURCES

  • Stock Research Overview
  • Stock Screeners
  • Markets & Sectors
  • Fidelity Learning Center Opens in New Window
Print Format
Change Text Size:
  • Default text sizeA
  • Larger text sizeA
  • Largest text sizeA

Price Of Pfizer's Paxlovid Generic Version Capped At $25 Or Less For Low-Income Countries

BY Benzinga
— 3:41 PM ET 05/12/2022
  • Several generic drugmakers will produce cheaper versions of Pfizer Inc's NYSE:PFE COVID-19 antiviral treatment Paxlovid at $25/course or less for low- and middle-income countries, Reuters reported citing the Clinton Health Access Initiative (CHAI).
  • CHAI said it could not disclose the manufacturers' names who have agreed to the price ceiling because they are still in the early stage of product development and have not received regulatory approval.
  • In March, 35 generic drugmakers signed on to make generic versions of Pfizer's pills for 95 poorer countries through a licensing arrangement with the U.N.-backed Medicines Patent Pool (MPP).
  • Pfizer sells Paxlovid to the U.S. government for about $530 for a five-day course.
  • CHAI said the generic drugmakers would dedicate capacity for 4.5 million treatment courses a month for these countries. 
  • The $25 price ceiling will apply if there is demand for at least 1 million treatment courses a year.
  • It said that orders need to be for at least 50,000 courses to guarantee the price.
  • A generic course of molnupiravir is expected to cost about $20 in poorer nations, compared with the roughly $700 per course Merck is charging the U.S.
  • Price Action: PFE shares are up 1.01% at $49.95 during the market session on the last check Thursday.

More MRK News

  • COCP: Cocrystal Pharma Releases 2022 1st Quarter Results and Provides an Update on the Current Pipeline Programs
    Benzinga - 12:10 PM ET 05/12/2022
  • Generic drugmakers to sell Pfizer's Paxlovid for $25 or less in low-income countries
    Reuters - 10:00 AM ET 05/12/2022
  • CNBC's Final Trades: Charles Schwab And These 3 Medical Stocks
    Benzinga - 7:52 AM ET 05/12/2022
Fidelity Investments. Copyright 1998–2022 FMR LLC. 
All rights reserved. 

  • Terms of Use|
  • Privacy|
  • Security|
  • Site Map 
Close